• 四川大學(xué)華西醫(yī)院老年科（成都610041）;

目的探討生長抑素類似物8肽（SS8）對人原發(fā)性肝癌細胞凋亡和cmyc蛋白表達的影響。方法體外培養(yǎng)肝癌細胞SMMC7721，用10 μg/ml SS8處理后，流式細胞儀檢測肝癌細胞凋亡率和cmyc蛋白的表達。結(jié)果與對照組相比，SS8使實驗組S期和G2/M期細胞數(shù)減少、G0/G1期細胞數(shù)增加，兩組細胞的凋亡率分別為6.1%和14.2%，差異有顯著性意義（P＜0.05）。經(jīng)SS8作用24 h后，實驗組cmyc蛋白表達水平為0.833±0.035，與對照組相比差異無顯著性意義（P＞0.10），而在SS8作用48、72、96、120和144 h后，實驗組cmyc蛋白表達水平分別為0.818±0.04、0.721±0.029、0.669±0.026、0.648±0.045和0.642±0.028，較對照組顯著降低（P＜0.05）。結(jié)論SS8有誘導(dǎo)肝癌細胞SMMC7721凋亡和降低cmyc蛋白表達的作用。

引用本文： 張燕玲,張正. 生長抑素類似物對肝癌細胞凋亡及c-myc蛋白表達的影響. 中國普外基礎(chǔ)與臨床雜志, 2003, 10(1): 25-27. doi: 復(fù)制

1. Robbins RJ. Somatostatin and cancer [Ｊ]. Metabolism，1996; 45(8 Suppl 1)∶98.
2. Srikant CB.Cell cycle dependent induction of apoptosis by somatostatin analog SMS201995 in AtT20 mouse pituitary cells [Ｊ]. Biochem Biophys Res Commun，1995; 209(2)∶400.
3. Reubi JC. Clinical relevance of somatostatin receptor imaging [Ｊ]. Eur J Endocrinol，1994; 131(6)∶575.
4. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease [Ｊ]. Trends Pharmacol Sci，1995; 16(3)∶110.
5. Sharma K, Patel YC, Srikant CB. Subtypeselective induction of wildtype p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3 [Ｊ]. Mol Endocrinol，1996; 10(12)∶1688.
6. Patel YC, Panetta R, Escher E,et al. Expression of multiple somatostatin receptor genes in AtT20 cells. Evidence for a novel somatostatin28 selective receptor subtype [Ｊ]. J Biol Chem， 1994; 269(2)∶1506.
7. Weinstein IB. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatmenttwentyseventh G.H.A. Clowes memorial award lecture [Ｊ]. Cancer Res，1988; 48(15)∶4135.
8. Stanbridge EJ. The reemergence of tumor suppression [Ｊ]. Cancer Cells, 1989; 1(1)∶31.
9. Lebovitz RM, Lieberman MW. Modulation of cellular genes by oncogenes [Ｊ]. Prog Nucleic Acid Res Mol Biol, 1988; 35∶73.
10. Pinto A, Attadia V, Rosati R,et al.Differentiation of human leukaemic cell lines and fresh leukaemia cells by low dose AraC: monitoring by expression of cmyc and cfos oncogenes [Ｊ]. Med Oncol Tumor Pharmacother, 1988; 5(2)∶91.
  1. 1. Robbins RJ. Somatostatin and cancer [Ｊ]. Metabolism，1996; 45(8 Suppl 1)∶98.
  2. 2. Srikant CB.Cell cycle dependent induction of apoptosis by somatostatin analog SMS201995 in AtT20 mouse pituitary cells [Ｊ]. Biochem Biophys Res Commun，1995; 209(2)∶400.
  3. 3. Reubi JC. Clinical relevance of somatostatin receptor imaging [Ｊ]. Eur J Endocrinol，1994; 131(6)∶575.
  4. 4. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease [Ｊ]. Trends Pharmacol Sci，1995; 16(3)∶110.
  5. 5. Sharma K, Patel YC, Srikant CB. Subtypeselective induction of wildtype p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3 [Ｊ]. Mol Endocrinol，1996; 10(12)∶1688.
  6. 6. Patel YC, Panetta R, Escher E,et al. Expression of multiple somatostatin receptor genes in AtT20 cells. Evidence for a novel somatostatin28 selective receptor subtype [Ｊ]. J Biol Chem， 1994; 269(2)∶1506.
  7. 7. Weinstein IB. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatmenttwentyseventh G.H.A. Clowes memorial award lecture [Ｊ]. Cancer Res，1988; 48(15)∶4135.
  8. 8. Stanbridge EJ. The reemergence of tumor suppression [Ｊ]. Cancer Cells, 1989; 1(1)∶31.
  9. 9. Lebovitz RM, Lieberman MW. Modulation of cellular genes by oncogenes [Ｊ]. Prog Nucleic Acid Res Mol Biol, 1988; 35∶73.
  10. 10. Pinto A, Attadia V, Rosati R,et al.Differentiation of human leukaemic cell lines and fresh leukaemia cells by low dose AraC: monitoring by expression of cmyc and cfos oncogenes [Ｊ]. Med Oncol Tumor Pharmacother, 1988; 5(2)∶91.